HDAC9 and cancer: The latter, comprising eighteen human HDAC isoforms, are promising targets for anti-cancer therapeutics, as HDAC inhibitors have demonstrated efficacy in inhibiting cancer proliferation by re-expressing suppressed regulatory genes [6, 7].